Search Market Research Report

Discover Our Latest Reports
Discover Our Featured Reports
Discover Top Selling Reports

RNAi for the Therapeutics Market Size, Share Global Analysis Report, 2019 – 2026

report img

RNAi for the Therapeutics Market by Type (siRNA, miRNA, and shRNA), and By Sales Channel (Direct & Distributor) for Cancer, Ocular Disorder, HBV and Others: Global Industry Perspective, Comprehensive Analysis and Forecast 2019 – 2026

Industry Insights

The report encompasses the forecast as well as an analysis of the RNAi for the Therapeutics market on the global and regional levels. The study displays historical data from 2016 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Million). Additionally, the market growth drivers, opportunities, limitations, and trends are also included in the RNAi for Therapeutic market report. 

We have included industry analysis models in our report and extensively demonstrated the key business strategies and competitive landscape of the RNAi for the Therapeutics market in our study.

RNAi for the Therapeutics Market Size

To know more about this report | Request Free Sample Copy


logoKey Insights from Primary Research

  • As per our primary respondents, the China RNAi for the Therapeutic market is around USD 27Million in 2018
  • It was established through primary research that the EuropeRNAi for Therapeutics market was valued at more than USD 70million in 2019
  • The siRNA, on the basis of product type, was the leading revenue-generating category accounting for more than two-thirds of the total market, in 2019.

logoKey Recommendations from Analysts

  • As per our analysis, siRNA for Therapeutic is an attractive segment for the RNAi Therapeutics market. The product has a high demand for Cancer Therapy
  • Growing at a CAGR of around 18.91%, Asia PacificRNAi for Therapeutic market accounts for numerous opportunities for all of the investors
  • Our analysts have identified, maximum patients of Cancers are being treated by using RNAi techniques.

logoGlobal Bone Void Filler Market Analysis: By Region

RNAi for the Therapeutics Market

To know more about this report | Request Free Sample Copy


Our study also includes an analysis of Porter’s Five Forces framework for understanding the competitive strategies used by market competitors. It also encompasses PESTLE analysis and SWOT analysis.

The report also offers an in-depth analysis of the market share of each industry player and gives an outline of the market position of key players in the RNAi for the Therapeutics market. Moreover, the study offers wide coverage of key strategic improvements witnessed in the market such as acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, R&D activities, and geographical expansion of key players of the RNAi for the Therapeutics market.

The study provides a decisive view of the RNAi for the Therapeutics market by segmenting the RNAi for the Therapeutics market based on type, sales channel, application, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2020 to 2026. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The global RNAi for the Therapeutics market is experiencing vibrant growth that is expected to continue over the upcoming years. Cancer associated with the Geriatric population across the world is likely to act as a key driver of the global RNAi for the Therapeutics market.

The RNAi for the Therapeutics market is segmented based on type, application, and region. Type-wise, the market is classified into siRNA, miRNA, and shRNA. In terms of application, the market segment is sectored into Cancer, Ocular Disorders, HBV, and Others.

logoReport Scope

Report Attribute

Details

Market Size in 2019

USD 27 Million

Projected Market Size in 2026

USD 70 million

CAGR Growth Rate

18.91% CAGR

Base Year

2019

Forecast Years

2020-2026

Key Market Players

Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Quark Pharmaceuticals, RXi Pharmaceuticals, miRagen Therapeutics, Gradalis, Sirnaomics, and Others

Key Segment

By Type, By Application, By Distribution, By Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Purchase Options

Request customized purchase options to meet your research needs. Explore purchase options

This report segments the global RNAi for the Therapeutics market as follows:

logoMajor Key market players are

  • Alnylam Pharmaceuticals
  • Arrowhead
  • Dicerna Pharmaceuticals
  • Quark Pharmaceuticals
  • RXi Pharmaceuticals
  • miRagen Therapeutics
  • Gradalis
  • Sirnaomics 

logo Type Analysis

  • siRNA
  • miRNA
  • shRNA

logo Application Analysis

  • Cancer
  • Ocular Disorder
  • HBV
  • Others

logo Distribution Analysis

  • Direct Channel
  • Distributor Channel

logo Regional Analysis

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-East Asia
    • Rest of Asia pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • The Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East & Africa

logoKey Pointers Addressed by the Report

  • Historical data and forecast analysis of the market
  • Drivers and Restraints affecting market dynamics
  • Exhaustive analysis of the future market trends
  • Comprehensive information about the leading market segments and region
  • Strategic developments made by the competitive players and in-depth analysis of its impact on market growth

Industry Major Market Players

  • Alnylam Pharmaceuticals
  • Arrowhead
  • Dicerna Pharmaceuticals
  • Quark Pharmaceuticals
  • RXi Pharmaceuticals
  • miRagen Therapeutics
  • Gradalis
  • Sirnaomics 

Frequently Asked Questions

Government policies and increasing funding for research and development is the major driving factor for the growth of the market.
The market for therapeutic RNAi is expected to grow from its current size of roughly USD 674.46 million to USD 2,493.73 million by 2026. From 2020 to 2026, the market for therapeutic RNAi is expected to grow at a CAGR of about 20.7%.
Asia Pacific contributes notably towards the global RNAi for the Therapeutics Market value
These are the major players in RNAi for the Therapeutics Market are Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Quark Pharmaceuticals, RXi Pharmaceuticals, miRagen Therapeutics, Gradalis, Sirnaomics, and Others